Pharmaceuticals company Lincoln Pharmaceuticals announced Q3FY26 results Revenue: Rs 166.32 lakh against Rs 146.55 lakh during Q3FY25, change 13%. EBITDA: Rs 38.74 lakh against Rs 32.63 lakh during Q3FY25, change 19%. PBT: Rs 34.72 lakh against Rs 28.68 lakh during Q3FY25, change 21%. PAT: Rs 28.6 lakh against Rs 20.77 lakh during Q3FY25, change 38%. EPS: Rs 14.28 for Q3FY26. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said: "We are pleased to deliver another strong quarter, reflecting consistent execution and resilient demand across all business verticals. We are strengthening our R&D; pipeline with over 100 new development programmes across multiple therapeutic segments and dosage forms, supported by bioequivalence studies and patent initiatives. These efforts reinforce our commitment to scientific innovation, unmet medical needs, and long-term. profitable growth. With a debt-free balance sheet, strong R&D; capabilities, and a healthy product pipeline, we remain confident of sustaining 15-18% annual growth and achieving our Rs 1,000 crore revenue target over the next three years." Result PDF